Cartalax

Cartalax is a synthetic tripeptide bioregulator (Ala-Glu-Asp) developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology in Russia. As a member of the Khavinson peptide family, Cartalax is a short bioregulatory peptide designed to target cartilage and connective tissue. Research suggests it supports chondrocyte function, promotes cartilage matrix synthesis, and helps regulate the balance between cartilage degradation and repair. Like other Khavinson peptides, Cartalax is proposed to act through epigenetic gene regulation rather than conventional receptor-mediated pharmacology.

Mechanism of Action

Cartalax is theorized to function through the Khavinson bioregulatory mechanism, where short peptides (2-4 amino acids) penetrate cell membranes and enter the nucleus to bind complementary DNA sequences in gene promoter regions. In cartilage and connective tissue, Cartalax is proposed to regulate expression of genes involved in chondrocyte proliferation, extracellular matrix synthesis (particularly collagen type II and proteoglycans), and the balance between matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs).

Research suggests Cartalax modulates expression of genes involved in chondrogenic differentiation, supporting the maintenance and renewal of cartilage tissue. The peptide has been studied for its ability to normalize the synthesis of glycosaminoglycans and structural proteins in cartilage, which typically decline with age. Cartalax also appears to have broader connective tissue effects, with research suggesting it supports telomere maintenance and cellular longevity in connective tissue cell populations, consistent with the anti-aging focus of the Khavinson peptide program.

Research Evidence

Khavinson et al. (2016, Bulletin of Experimental Biology and Medicine): demonstrated that Cartalax (Ala-Glu-Asp) regulated gene expression in cartilage cell cultures and promoted synthesis of cartilage matrix components. The tripeptide increased expression of chondrogenic markers while suppressing inflammatory mediators associated with cartilage degradation.

Linkova et al. (2016): showed that short peptides including the Ala-Glu-Asp sequence interact with specific DNA regions, supporting the epigenetic mechanism of action. Khavinson et al. (2020): reported that Cartalax treatment extended telomere length and improved markers of cellular senescence in connective tissue fibroblast cultures, linking cartilage bioregulation to broader anti-aging mechanisms.

Clinical Applications

In Russian clinical practice, Cartalax has been used to support cartilage repair in osteoarthritis and degenerative joint conditions, recovery from joint injuries and surgical procedures, age-related cartilage degeneration, and general musculoskeletal bioregulation in aging populations. Russian clinicians have reported improvements in joint mobility, reduction in pain scores, and slowed progression of degenerative cartilage changes when Cartalax is incorporated into treatment protocols. Internationally, Cartalax is of research interest for its potential to promote cartilage regeneration through epigenetic mechanisms, an important area given the limited self-repair capacity of adult articular cartilage.